DeepMed Research

University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Irinotecan
Drug: Capecitabine

First Posted Date: 2007-06-07

Last Posted Date: 2019-02-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 50

Registration Number: NCT00483834

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Drug: Sunitinib Malate (Sutent)

First Posted Date: 2007-05-31

Last Posted Date: 2015-12-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 3

Registration Number: NCT00480935

Locations: 🇨🇦
University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada

A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Cytarabine

First Posted Date: 2007-05-30

Last Posted Date: 2019-02-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 10

Registration Number: NCT00480090

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark

Phase 2

Conditions: Type 2 Diabetes
Hypercholesterolemia

Interventions: Dietary Supplement: Cinnamonforce
Dietary Supplement: Placebo

First Posted Date: 2007-05-30

Last Posted Date: 2007-11-20

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 70

Registration Number: NCT00479973

Locations: 🇨🇦
UHN - Toronto Western Hospital, Toronto, Ontario, Canada
🇨🇦
Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada

Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal

Phase 2

Completed

Conditions: Renal Cell Carcinoma
Metastatic Disease

Interventions: Drug: Sorafenib

First Posted Date: 2007-05-30

Last Posted Date: 2015-12-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 19

Registration Number: NCT00480389

Locations: 🇨🇦
Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Hodgkin Disease

Interventions: Drug: Lenalidomide (Revlimid®)

First Posted Date: 2007-05-25

Last Posted Date: 2020-09-18

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 30

Registration Number: NCT00478959

CVD Risk Reduction Trial

Not Applicable

Completed

Conditions: Cardiovascular Disease

First Posted Date: 2007-05-15

Last Posted Date: 2007-05-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 827

Registration Number: NCT00473785

Locations: 🇨🇦
Grey-Bruce Health Unit, Owen Sound, Ontario, Canada
🇨🇦
Laurentian University / Sudbury and District Health Unit, Sudbury, Ontario, Canada
🇨🇦
University Health Network / Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada

Study of Methotrexate in Lupus Erythematosus

Phase 3

Completed

Conditions: Systemic Lupus Erythematosus

First Posted Date: 2007-05-07

Last Posted Date: 2007-05-07

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 86

Registration Number: NCT00470522

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2007-04-19

Last Posted Date: 2018-02-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 25

Registration Number: NCT00462995

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib

Phase 4

Terminated

Conditions: Chronic Myeloid Leukemia
Chromosome Abnormality
Gastrointestinal Stromal Cell Tumors

First Posted Date: 2007-04-18

Last Posted Date: 2009-02-13

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 68

Registration Number: NCT00461929

Locations: 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy